Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Drug company (FDA labeler)

GE Healthcare

NDC labeler code: 0407

What is a labeler?

The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.

Official FDA data only

Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.

Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.

At a glance

3Products (NDC)

Prescription medicines

FDA applications for these products

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
ApprovedApplicationMedicineSponsor
November 1, 2019ANDA210016 Gadoterate meglumine
CLARISCAN
Ge Healthcare
October 24, 1995NDA020608 Iohexol
OMNIPAQUE 240, OMNIPAQUE 300, OMNIPAQUE 350
Ge Healthcare

The sponsor is the company that holds the FDA application; it can differ from the labeler.

Recall timeline

2026

  1. March 24, 2026 · Class II · Ongoing · D-0448-2026 · Iohexol

    Presence of particulate matter

    GE Healthcare Omnipaque (iohexol) Injection, 350 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1414-91.

  2. March 24, 2026 · Class II · Ongoing · D-0447-2026 · Iohexol

    Presence of particulate matter

    GE Healthcare Omnipaque (iohexol) Injection, 300 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1413-63.

2018

  1. October 29, 2018 · Class II · Terminated · D-0319-2019 · Iohexol

    Defective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for glass particles.

    Omnipaque (iohexol) Injection, 180mgI/mL, 20 mL Single-Dose Vial, packaged in 10 x 20 mL Vials per carton, Rx only, Distributed by GE Healthcare Inc., Marlborough, MA 01752 U.S.A.; Manufactured by GE Healthcare AS, Oslo,

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026

FDA Enforcement Report search → · Report an error →